<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="149799">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02077088</url>
  </required_header>
  <id_info>
    <org_study_id>1.090</org_study_id>
    <nct_id>NCT02077088</nct_id>
  </id_info>
  <brief_title>Effect of Galactooligosaccharides on Incidence of Atopic Manifestations in Infants</brief_title>
  <official_title>Double Blind, Randomised Study on the Effect of Prebiotics on Incidence of Atopic Manifestations in Infants</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Humana Co.Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Vitkovice Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Humana Co.Ltd.</source>
  <oversight_info>
    <authority>Czech Republic: Ethics Committee</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Addition of prebiotic galactooligosaccharides to hypoallergenic starter formula would lead
      to decreased allergic (atopic) symptoms in nonbreastfed infants with a positive history of
      allergy in family
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">April 2013</completion_date>
  <primary_completion_date type="Actual">November 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>SCORAD (SCORing Atopic  Dermatitis score) assessment of atopy</measure>
    <time_frame>at  6 months of age</time_frame>
    <safety_issue>No</safety_issue>
    <description>objective evaluation of atopic symptoms</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>anthropometric parameters (height, weight)</measure>
    <time_frame>at  6 months of age</time_frame>
    <safety_issue>Yes</safety_issue>
  </secondary_outcome>
  <other_outcome>
    <measure>incidence of febrile episodes</measure>
    <time_frame>at 6 months</time_frame>
    <safety_issue>Yes</safety_issue>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">120</enrollment>
  <condition>Atopic Dermatitis</condition>
  <arm_group>
    <arm_group_label>Galactooligosaccharides</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>addition of 0,5g galactooligosaccharides to HA (hypoallergenic) starter formula</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Only HA formula</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>only standard HA starter formula</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>galactooligosaccharide</intervention_name>
    <description>addition of food grade GRAS (Generally Regarded As Safe) galactooligosaccharides</description>
    <arm_group_label>Galactooligosaccharides</arm_group_label>
    <other_name>GOS</other_name>
    <other_name>prebiotics</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  nonbreastfed eutrophic infants of corresponding gestational age

          -  presence of a positive family allergic anamnesis in parents or siblings (atopic
             eczema,   allergic rhinitis or bronchial asthma)

        Exclusion Criteria:

          -  children with serious disease,

          -  breastfed children

          -  children fed another formula then the ones used
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>8 Weeks</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Bozensky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vitkovice Hospital, Ostrava, Czech Republic</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vitkovice Hospital</name>
      <address>
        <city>Ostrava-Vitkovice</city>
        <zip>70384</zip>
        <country>Czech Republic</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Czech Republic</country>
  </location_countries>
  <verification_date>February 2014</verification_date>
  <lastchanged_date>February 28, 2014</lastchanged_date>
  <firstreceived_date>January 2, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>interventional</keyword>
  <keyword>doubleblind</keyword>
  <keyword>randomised</keyword>
  <keyword>pediatric</keyword>
  <keyword>prebiotic</keyword>
  <keyword>atopic</keyword>
  <keyword>dermatitis</keyword>
  <keyword>infant</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Dermatitis</mesh_term>
    <mesh_term>Dermatitis, Atopic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
